MET Amplification Clinical Trials
0 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital60 enrolled1 locationNCT07322783
Recruiting
Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Pancreatic CancerGastric CancerLung Cancer+15 more
Apollomics Inc.497 enrolled35 locationsNCT03175224